Last edition
News about "ONO Pharmaceutical "
Ono Pharmaceutical Partners with Congruence Therapeutics for Neurology and Immunology Drug Discovery
Ono Pharmaceutical has expanded its collaboration with Congruence Therapeutics, leveraging the Revenir platform to discover small molecule modulators in neurology and immunology. Ono will hold exclusive worldwide option rights for development and commercialisation of resulting candidates.
Ono Pharmaceutical | 03/03/2026 | By Akanki | 135
Ono Pharmaceutical has signed a definitive agreement with Seikagaku Corporation for the co-development and exclusive marketing of Gel-One for osteoarthritis treatment in Japan.
Ono Pharmaceutical | 11/08/2025 | By Mrinmoy Dey | 344
Ono and Congruence to Generate Novel Small Molecule Correctors in Oncology Area
Under the terms of the agreement, Congruence will generate small molecule correctors by leveraging Congruence's proprietary drug discovery engine called, Revenir™.
Ono Pharmaceutical | 07/12/2024 | By Aishwarya | 489
Ono Announces Acquisition of Deciphera Pharmaceuticals
Ono Pharmaceutical, Co., Ltd. has completed the tender offer to acquire all outstanding shares of common stock of a US biopharmaceutical company, Deciphera Pharmaceuticals, Inc. for USD 25.60 per share (total amount of approximately USD 2.4 billion) net to the seller in cash.
Ono Pharmaceutical | 14/06/2024 | By Aishwarya | 734
ONO to Acquire Deciphera Pharma for USD 2.4 Billion
Deciphera Pharmaceuticals, Inc. has signed a definitive merger agreement with ONO Pharmaceutical Co., Ltd. (ONO).
ONO Pharmaceutical | 30/04/2024 | By Aishwarya | 417
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy